STOCKHOLM, June 17 /PRNewswire/ -- Karolinska Development announced that the talk will focus on the commercialization mechanism behind the Karolinska Institutet Innovations System set up by Karolinska Institutet. Bogentoft, is CEO of Karolinska Development (KD), one of the largest life science investment companies in Europe. Using a unique highly cost effective model to commercialize innovative life science from Northern Europe KD capitalizes on the value appreciation generated by bringing very early projects to proof of concept.

This talk will cover the key points that have enabled KD to build a portfolio in less than 5 years that, has three companies with products on the market; four with compounds at phase II and five with compounds at phase I.

The unique evergreen structure and exclusive deal flow from Karolinska Institutet Innovations AB enable innovations to be taken from seed stage through to optimal exit. Ensuring access to appropriate milestone driven capital funding and key competencies required in each development phase enables companies to mature rapidly.

Providing far more than seed capital Karolinska Development also provides companies with the skills and expertise needed in order to build value efficiently. The Karolinska Development management has long industrial experience within development and business, contributing senior R&D expertise that accelerates product and business development. This management team is supplemented a network of experts that includes more than 300 specialists, including; project managers, business development experts, general management and board members from a range of companies.

About Karolinska Development AB

Karolinska Development commercializes Nordic life science innovation. Early stage investment enables value building through long term lead investor position, from seed stage to the market.

About Karolinska Institutet

Karolinska Institutet is one of the leading medical universities in Europe. Through research, education and information, Karolinska Institutet contributes to improving human health. Each year, the Nobel Assembly at Karolinska Institutet awards the Nobel Prize in Physiology or Medicine. For more information, visit

For more information please contact: Conny Bogentoft, CEO Karolinska Development, +46(0)70-668-61-43,